Company Performance Metrics
- Hsiao-Wei Tang: CEO
Maxima Biotech Inc., established in April 2019, has rapidly emerged as a dynamic and innovative force in the medical device industry. Specializing in the rapid commercialization of minimally invasive surgical (MIS) products, the company positions itself as a strategic partner for global medtech leaders and innovators by delivering a unique
combination of cutting-edge innovation and cost-effective manufacturing solutions. Headquartered in the technological hub of Taiwan, Maxima Biotech harnesses Taiwan's world-renowned electronic and precision manufacturing capabilities and engineering talents. This strategic location provides us with a significant competitive edge in the global medical device market, enabling us to leverage Taiwan's formidable strengths in innovation, high-tech manufacturing, and streamlined supply chain management. Our commitment to groundbreaking innovation is powerfully demonstrated by our recent achievement: the development of the world's second cordless ultrasonic dissector. This state-of-the-art device, brought to market in an unprecedented three-year timeframe, exemplifies our ability to swiftly create and commercialize advanced surgical tools that set new industry standards. This accelerated development cycle showcases both our technical prowess and our agility in responding to market needs while expediting the journey from concept to commercialization. By combining Taiwan's manufacturing excellence with our innovative approach to product development, Maxima Biotech is uniquely positioned to deliver high-quality, cost-effective MIS solutions that meet the evolving demands of the global healthcare industry. Our proven track record in bringing cutting-edge devices to market efficiently underscores our value as an essential partner for healthcare leaders seeking to stay at the forefront of medical technology.